Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A consensus statement for the management for patients of all ages with all stages of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) - All StAGEs - is proposed by representatives of the UK National Cancer Research Institute (NCRI) Hodgkin lymphoma study group and the Children's Cancer & Leukaemia Group. Based on current practices and published evidence, a consensus has been reached regarding diagnosis, staging and risk-ik7 stratified management which includes active surveillance, low- and standard-dose immunochemotherapy and radiotherapy.

Original publication

DOI

10.1111/bjh.18169

Type

Journal

Br J Haematol

Publication Date

06/2022

Volume

197

Pages

679 - 690

Keywords

all ages, all stages, low-intensity chemotherapy, radiotherapy, rituximab, transformation, Academies and Institutes, Adult, Child, Consensus, Hodgkin Disease, Humans, Lymphocytes, United Kingdom